Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

<< Previous

Bullboard Posts

Next >>

Post by ETFguyon Dec 14, 2020 8:01pm

208 Views

Post# 32105914

Potential !

Potential here is huge, natural treatment for anxiety. What percentage of US has anxiety, 2017 estimate was about 19%.
How about now with this Corona bussiness, and here we are talking about natural treatment.

Once they get FDA approval, there is big chance of take over by big pharma, those companies are behind in this kind of treatment.

How high this baby will go, who knows, just tighten your seat belt and enjoy the ride !

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects